SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 4845-4846

Objective response rate as a surrogate end point: A commentary

(1) Fleming, Thomas R a

a UNIVERSITY OF WASHINGTON (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PROSTATE SPECIFIC ANTIGEN; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; EDITORIAL; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VALIDITY; BIOASSAY; BREAST TUMOR; FEMALE; METASTASIS; NOTE; PATHOLOGY; SURVIVAL;

BREAST NEOPLASMS; ENDPOINT DETERMINATION; FEMALE; HUMANS; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 24644506259 PISSN: 0732183X EISSN: None Source Type: Journal
DOI: 10.1200/JCO.2005.92.008 Document Type: Editorial

Times cited : (24)

References (7)

1
- 24644440601
- Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
- Bruzzi P, Del Mastro L, Sormani MP, et al: Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 23:5117-5126, 2005
- (2005) J Clin Oncol , vol.23 , pp. 5117-5126
- Bruzzi, P.¹ Del Mastro, L.² Sormani, M.P.³

2
- 12944288028
- Surrogate end points and FDA's accelerated approval process
- Fleming TR: Surrogate end points and FDA's accelerated approval process. Health Aff 24:67-78, 2005
- (2005) Health Aff , vol.24 , pp. 67-78
- Fleming, T.R.¹

3
- 0026573094
- Statistical validation of intermediate end points for chronic diseases
- Freedman LS, Graubard BL, Schatzkin A: Statistical validation of intermediate end points for chronic diseases. Stat Med 11:167-178, 1992
- (1992) Stat Med , vol.11 , pp. 167-178
- Freedman, L.S.¹ Graubard, B.L.² Schatzkin, A.³

4
- 0031029644
- Validating surrogate markers: Are we being naïve?
- DeGruttola V, Fleming TR, Coombs R, et al: Validating surrogate markers: Are we being naïve? J Infect Dis 175:237-246, 1997
- (1997) J Infect Dis , vol.175 , pp. 237-246
- DeGruttola, V.¹ Fleming, T.R.² Coombs, R.³

5
- 0030771191
- Estimating the proportion of treatment effect explained by a surrogate marker
- Lin DY, Fleming TR, DeGruttola V: Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 16:1515-1527, 1997
- (1997) Stat Med , vol.16 , pp. 1515-1527
- Lin, D.Y.¹ Fleming, T.R.² DeGruttola, V.³

6
- 0021343213
- A nonparametric graphical presentation of the relationship between survival and the occurrence of an event: Application to responders versus nonresponders bias
- Simon R, Makuch RW: A nonparametric graphical presentation of the relationship between survival and the occurrence of an event: Application to responders versus nonresponders bias. Stat Med 3:35-44, 1984
- (1984) Stat Med , vol.3 , pp. 35-44
- Simon, R.¹ Makuch, R.W.²

7
- 33846893268
- Disease-free survival versus overall survival as an end point for adjuvant colon cancer studies: Data from randomized trials
- Washington DC, March 12-13
- Sargent D: Disease-free survival versus overall survival as an end point for adjuvant colon cancer studies: Data from randomized trials. Meeting Transcript of the United States Food and Drug Administration Oncology Drugs Advisory Committee, Washington DC, March 12-13, 2003
- (2003) Meeting Transcript of the United States Food and Drug Administration Oncology Drugs Advisory Committee
- Sargent, D.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.